CC
MRNA icon

Capital Counsel’s Moderna MRNA Stock Holding History

Capital Counsel’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$315K Buy
+6,202
New +$289K 0.01% 50
2025
Q2 		– Sell
-8,727
Closed -$247K – 60
2025
Q1 		$247K Sell
8,727
-13
-0.1% -$461 0.01% 47
2024
Q4 		$363K Sell
8,740
-330
-4% -$15.8K 0.02% 43
2024
Q3 		$606K Hold
9,070
– – 0.03% 36
2024
Q2 		$1.08M Sell
9,070
-900
-9% -$114K 0.05% 30
2024
Q1 		$1.06M Sell
9,970
-431
-4% -$43.4K 0.05% 31
2023
Q4 		$1.03M Sell
10,401
-170
-2% -$14.3K 0.05% 32
2023
Q3 		$1.09M Buy
10,571
+2,353
+29% +$262K 0.06% 29
2023
Q2 		$998K Hold
8,218
– – 0.06% 30
2023
Q1 		$1.26M Buy
8,218
+450
+6% +$74.2K 0.07% 29
2022
Q4 		$1.4M Buy
7,768
+21
+0.3% +$3.43K 0.09% 26
2022
Q3 		$916K Buy
7,747
+30
+0.4% +$4.55K 0.06% 30
2022
Q2 		$1.1M Buy
7,717
+24
+0.3% +$3.43K 0.07% 29
2022
Q1 		$1.32M Sell
7,693
-6
-0.1% -$1.01K 0.06% 28
2021
Q4 		$1.96M Sell
7,699
-91
-1% -$26.6K 0.08% 24
2021
Q3 		$3M Sell
7,790
-50
-0.6% -$18.4K 0.15% 21
2021
Q2 		$1.84M Sell
7,840
-180
-2% -$32.2K 0.09% 26
2021
Q1 		$1.05M Buy
+8,020
New +$1.16M 0.06% 32

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Counsel's MRNA Position: Q1 2026 in Review

Capital Counsel opened a new position in Moderna (MRNA) in Q1 2026: 6,202 shares worth $315K. The stake represents 0.01% of the portfolio and ranks #50 among its holdings. This is a return to the name: Capital Counsel previously reported a position in MRNA as recently as Q1 2025.

Capital Counsel first reported a position in MRNA in Q1 2021 and has held it in 18 quarters since. The position peaked at $3M in Q3 2021. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Capital Counsel held 6,202 shares of Moderna worth $315K as of Q1 2026.
  • Moderna was a new Capital Counsel position in Q1 2026.
  • Moderna made up 0.01% of Capital Counsel's portfolio in Q1 2026, its #50 holding.
  • Capital Counsel first reported a position in Moderna in Q1 2021 and has held it in 18 quarters since.
  • Capital Counsel's Moderna position peaked at $3M in Q3 2021.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Capital Counsel's 13F filing for Q1 2026, filed 15 May 2026.